keyword
MENU ▼
Read by QxMD icon Read
search

Tumor infiltrating lymphocyte breast

keyword
https://www.readbyqxmd.com/read/29676353/interobserver-reproducibility-of-tumor-infiltrating-lymphocyte-evaluations-in-breast-cancer
#1
Fatmagul Kusku Cabuk, Fatma Aktepe, Fatma Nilgun Kapucuoglu, Ipek Coban, Dauren Sarsenov, Vahit Ozmen
Aim: Tumor-infiltrating lymphocytes (TILs) have a prognostic value in breast cancer (BC); however, because of the lack of standard evaluation methods, we aimed to assess the interobserver agreement of stromal TILs (sTILs) and intratumoral TILs (iTILs) as well as the effect of hot spot areas and molecular subtyping on the overall agreement. Methods: The study consisted of 121 haematoxylin and eosin (H and E)-stained slides of invasive BC samples obtained from the pathology archives...
April 2018: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/29661777/interferon-stimulated-genes-are-involved-in-cross-resistance-to-radiotherapy-in-tamoxifen-resistant-breast-cancer
#2
Annemarie E M Post, Marcel Smid, Anika Nagelkerke, John W M Martens, Johan Bussink, Fred Cjg Sweep, Paul N Span
PURPOSE: Treatment resistance is a main cause of adverse disease outcome in breast cancer patients. Here we aimed to investigate common features in tamoxifen-resistant and radioresistant breast cancer, since tamoxifen-resistant breast cancer cells are cross-resistant to irradiation in vitro. EXPERIMENTAL DESIGN: RNA sequencing of tamoxifen-resistant and radioresistant breast cancer cells was performed and validated by quantitative PCR. Pathways were further investigated in vitro and in breast cancer patient cohorts to establish their relation with treatment resistance...
April 16, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29651385/clinicopathological-predictors-of-long-term-benefit-in-breast-cancer-treated-with-neoadjuvant-chemotherapy
#3
Marco Galvez, Carlos A Castaneda, Joselyn Sanchez, Miluska Castillo, Lia Pamela Rebaza, Gabriela Calderon, Miguel De La Cruz, Jose Manuel Cotrina, Julio Abugattas, Jorge Dunstan, Henry Guerra, Omar Mejia, Henry L Gomez
AIM: To investigate the survival impact of clinicopathological factors, including pathological complete response (pCR) and tumor-infiltrating lymphocytes (sTIL) levels according to subtypes, in breast cancer (BC) patients who received neo-adjuvant chemotherapy (NAC). METHODS: We evaluated 435 BC patients who presented and received NAC at the Instituto Nacional de Enfermedades Neoplasicas from 2003 to 2014. sTIL was analyzed as the proportion of tumor stroma occupied by lymphocytes, and was prospectively evaluated on hematoxylin and eosin-stained sections of the preNAC core biopsy...
April 10, 2018: World Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29628983/-fcrr3a-158-polymorphism-and-stromal-tumor-infiltrating-lymphocytes-and-survival-among-patients-with-metastatic-her2-positive-breast-cancer-receiving-trastuzumab-based-treatment
#4
Heejung Chae, Changhoon Yoo, Jung-A Yoon, Hee Jin Lee, Kyu-Pyo Kim, Jeong-Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Gyungyub Gong, Sung-Bae Kim
Purpose: The prognosis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer has markedly improved since the introduction of trastuzumab. We aimed to evaluate the association between stromal tumor-infiltrating lymphocyte (sTIL) or FcrR polymorphisms and survival among patients with metastatic HER2-positive breast cancer who were treated with trastuzumab. Methods: A total of 56 women with recurrent or metastatic HER2-positive breast cancer who received the trastuzumab-taxane combination as first-line treatment were included in this retrospective analysis...
March 2018: Journal of Breast Cancer
https://www.readbyqxmd.com/read/29615305/early-stage-her2-positive-breast-cancers-not-achieving-a-pcr-from-neoadjuvant-trastuzumab-or-pertuzumab-based-regimens-have-an-immunosuppressive-phenotype
#5
Jeremy Force, Lynn J Howie, Sara E Abbott, Rex Bentley, P Kelly Marcom, Gretchen Kimmick, Kelly Westbrook, Sarah L Sammons, Michelle Parks, Donna L Topping, Ryan Emerson, Gloria Broadwater, Terry Hyslop, Kimberly L Blackwell, Smita K Nair
BACKGROUND: Stromal tumor-infiltrating lymphocytes (TILs) might predict pathologic complete response (pCR) in patients with HER2-positive (HER2+ ) breast cancer treated with trastuzumab (H). Docetaxel (T), carboplatin (C), H, and pertuzumab (P) have immune-modulating effects. Pre- and post-treatment immune biomarkers in cancers treated with neoadjuvant TCH with or without P are lacking. In this study we quantified baseline and changes in TILs, cluster of differentiation (CD) 4+ , CD8+ , FoxP3+ , and PD-L1+ cells using immunohistochemistry (IHC) and quantified productive T-cell receptor β (TCRβ) rearrangements and TCRβ clonality using next-generation sequencing (NGS) in 30 HER2+ breast cancer tissues treated with neoadjuvant H with or without P regimens...
February 24, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29615076/use-of-the-tumor-infiltrating-cd8-to-foxp3-lymphocyte-ratio-in-predicting-treatment-responses-to-combination-therapy-with-pertuzumab-trastuzumab-and-docetaxel-for-advanced-her2-positive-breast-cancer
#6
Koji Takada, Shinichiro Kashiwagi, Wataru Goto, Yuka Asano, Katsuyuki Takahashi, Tsutomu Takashima, Shuhei Tomita, Masahiko Ohsawa, Kosei Hirakawa, Masaichi Ohira
BACKGROUND: The trastuzumab, pertuzumab, and docetaxel (TPD) regimen is strongly recommended as a treatment option for first-line therapy for advanced human epidermal growth factor receptor (HER) 2-positive breast cancer. Monitoring the host microenvironments in cancer plays a significant role in predicting prognoses and curative effects. It is important to clarify the role of immune related gene expression in tumor-infiltrating lymphocytes in the tumor microenvironment. In this study, we evaluated the impact of chemotherapy with a TPD regimen, on immune micro environments in HER2-positive breast cancer using immune related proteins as indicators...
April 3, 2018: Journal of Translational Medicine
https://www.readbyqxmd.com/read/29599354/prediction-of-treatment-response-to-neoadjuvant-chemotherapy-in-breast-cancer-by-subtype-using-tumor-infiltrating-lymphocytes
#7
Yuka Asano, Shinichiro Kashiwagi, Wataru Goto, Koji Takada, Katsuyuki Takahashi, Takaharu Hatano, Tsutomu Takashima, Shuhei Tomita, Hisashi Motomura, Masahiko Ohsawa, Kosei Hirakawa, Masaichi Ohira
BACKGROUND/AIM: Recent interest has focused on the significance of tumor-infiltrating lymphocytes (TILs) on the efficacies and outcomes of the treatment in breast cancer (BC). Based on the recent international recommendation to standardize the evaluation method, the clinical validity and utility of TILs in patients who underwent neoadjuvant chemotherapy (NAC) were investigated in the present study. PATIENTS AND METHODS: TILs were evaluated in 177 patients with BC treated with NAC and subsequent curative surgery...
April 2018: Anticancer Research
https://www.readbyqxmd.com/read/29588392/tumor-infiltrating-lymphocytes-and-pd-l1-expression-in-pre-and-post-treatment-breast-cancers-in-the-swog-s0800-phase-ii-neoadjuvant-chemotherapy-trial
#8
Vasiliki Pelekanou, William E Barlow, Zeina Nahleh, Brad Wasserman, Ying-Chun Lo, Marie-Kristin von Wahlde, Daniel F Hayes, Gabriel N Hortobagyi, Julie R Gralow, Debu Tripathy, Peggy L Porter, Borbala Szekely, Christos Hatzis, David L Rimm, Lajos Pusztai
Our aim was to examine the association of pre-treatment tumor infiltrating lymphocyte (TIL) count and PD-L1 levels with pathologic complete response (pCR) and assess immune marker changes following treatment in tumor specimens from the S0800 clinical trial which randomized patients to bevacizumab+nab-paclitaxel followed by doxorubicin/cyclophosphamide (AC) versus two control arms without bevacizumab (varying sequence of AC and nab-paclitaxel). TILs were assessed in 124 pre- and 62 post-treatment tissues (including 59 pairs)...
March 27, 2018: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/29581131/higher-absolute-lymphocyte-counts-predict-lower-mortality-from-early-stage-triple-negative-breast-cancer
#9
Anosheh Afghahi, Natasha Purington, Summer S Han, Manisha Desai, Emma Pierson, Maya B Mathur, Tina Seto, Caroline A Thompson, Joseph Rigdon, Melinda L Telli, Sunil S Badve, Christina Curtis, Robert B West, Kathleen Horst, Scarlett Lin Gomez, James M Ford, George W Sledge, Allison W Kurian
BACKGROUND: Tumor-infiltrating lymphocytes (TILs) in pre-treatment biopsies are associated with improved survival in triple-negative breast cancer (TNBC). We investigated whether higher peripheral lymphocyte counts are associated with lower breast cancer-specific mortality (BCM) and overall mortality (OM) in TNBC. METHODS: Data on treatments and diagnostic tests from electronic medical records of two healthcare systems were linked with demographic, clinical, pathologic, and mortality data from the California Cancer Registry...
March 26, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29573739/comparisons-of-tumor-infiltrating-lymphocyte-levels-and-the-21-gene-recurrence-score-in-er-positive-her2-negative-breast-cancer
#10
Sung Gwe Ahn, Yoon Jin Cha, Soon June Bae, Chanik Yoon, Hak Woo Lee, Joon Jeong
BACKGROUND: Recent studies have shown that tumors with extensive tumor-infiltrating lymphocytes (TILs) have a higher probability of pathologic complete response, even in luminal/human epidermal growth factor 2 (HER2)-negative breast cancer. We compared TIL levels and the 21-gene recurrence score (RS) in estrogen receptor (ER)-positive/HER2-negative breast cancer. METHODS: We evaluated the percentage of stromal TILs in 198 ER-positive/HER2-negative patients in whom RS was obtained by examining slides of surgical specimens by standardized methodology proposed by the international TIL Working Group...
March 24, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29568299/new-insights-into-tumor-infiltrating-b-lymphocytes-in-breast-cancer-clinical-impacts-and-regulatory-mechanisms
#11
REVIEW
Meng Shen, Jian Wang, Xiubao Ren
Currently, tumor-infiltrating B lymphocytes have been recognized as a new hallmark of breast cancer (BC). The function seems to be controversial, either with positive, negative, or no significance in BC's prediction and prognosis. Moreover, B-cell infiltrates regulate tumor process through productions of antibodies and interleukin-10. The interactions with other lymphocytes and programmed death-1/PD-1 ligand axis are also documented. The regulatory mechanisms will eventually be incorporated into diagnostic and therapeutic algorithms, thus give guide to clinical treatment...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29559742/prognostic-significance-of-tumor-infiltrating-lymphocytes-in-ductal-carcinoma-in-situ-of-the-breast
#12
Michael S Toss, I Miligy, Abdubaqi Al-Kawaz, Mansour Alsleem, Hazem Khout, Padmashree C Rida, Ritu Aneja, Andrew R Green, Ian O Ellis, Emad A Rakha
Tumor-infiltrating lymphocytes (TILs) provide prognostic value in invasive breast cancer and guidelines for their assessment have been published. This study aims to evaluate: (a) methods of TILs assessment, and (b) their prognostic significance in breast ductal carcinoma in situ (DCIS). Hematoxylin and eosin sections from two clinically annotated DCIS cohorts; a training set (n = 150 pure DCIS) and a validation set (n = 666 comprising 534 pure DCIS and 132 cases wherein DCIS and invasive breast carcinoma were co-existent) were assessed...
March 20, 2018: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/29559701/effect-of-ccl5-expression-in-the-recruitment-of-immune-cells-in-triple-negative-breast-cancer
#13
Jhajaira M Araujo, Andrea C Gomez, Alfredo Aguilar, Roberto Salgado, Justin M Balko, Leny Bravo, Franco Doimi, Denisse Bretel, Zaida Morante, Claudio Flores, Henry L Gomez, Joseph A Pinto
Triple negative breast cancer (TNBC) is the most aggressive form of breast cancer with limited options of targeted therapy. Recent findings suggest that the clinical course of TNBC may be modified by the presence of tumor-infiltrating lymphocytes (TILs) and chemokine's expression, such as CCL5. Diverse studies have shown that CCL5 suppresses anti-tumor immunity and it has been related to poor outcome in different types of cancer while in other studies, this gene has been related with a better outcome. We sought to determine the association of CCL5 with the recruitment of TILs and other immune cells...
March 20, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29534901/abscopal-effects-with-hypofractionated-schedules-extending-into-the-effector-phase-of-the-tumor-specific-t-cell-response
#14
Xuanwei Zhang, Gabriele Niedermann
PURPOSE: Hypofractionated radiation therapy (hRT) combined with immune checkpoint blockade can induce T-cell-mediated local and abscopal antitumor effects. We had previously observed peak levels of tumor-infiltrating lymphocytes (TILs) between days 5 and 8 after hRT. Because TILs are regarded as radiosensitive, hRT schedules extending into this period might be less immunogenic, prompting us to compare clinically relevant, short and extended schedules with equivalent biologically effective doses combined with anti-programmed cell death 1 (PD1) antibody treatment...
February 3, 2018: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29524062/the-role-of-programmed-death-ligand-1-and-tumor-infiltrating-lymphocytes-in-breast-cancer-overexpressing-her2-gene
#15
Yanchun Li, Mateusz Opyrchal, Song Yao, Xuan Peng, Li Yan, Hossam Jabbour, Thaer Khoury
PURPOSE: The purpose of the study is to investigate the prognostic significance of programmed death ligand-1 (PD-L1) expression and tumor-infiltrating lymphocytes (TILs) in HER2+ breast cancer (BC). METHODS: HER2+ BC cases (n  = 191) were collected between 1996 and 2013. Tissue microarray (TMA) slides were stained with two clones of PD-L1 antibodies (28-8 and 22C3) and the percentage of positive membranous staining was scored. TILs of the full sections were also scored using percentage scale...
March 9, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29523158/study-on-the-progression-types-of-cancer-in-patients-with-breast-cancer-undergoing-eribulin-chemotherapy-and-tumor-microenvironment
#16
Shinichiro Kashiwagi, Gen Tsujio, Yuka Asano, Wataru Goto, Koji Takada, Katsuyuki Takahashi, Tamami Morisaki, Hisakazu Fujita, Tsutomu Takashima, Shuhei Tomita, Masahiko Ohsawa, Kosei Hirakawa, Masaichi Ohira
BACKGROUND: Recently, the concepts of progression due to pre-existing lesions (PPL) and progression due to new metastasis (PNM) have been proposed to differentiate the progression types of treatment-resistant cancers. Previously, the differences between these two progression types did not affect the determination of treatment strategies since both PPL and PNM are classified as progressive disease based on the response evaluation criteria in solid tumors (RECIST) diagnostic criteria. On the other hand, tumor infiltrating lymphocytes (TILs) are effective when used as indicators for monitoring the immune tumor microenvironment (iTME) in the cancer host, and TILs play an important role as biomarkers in predicting prognosis and therapeutic effects...
March 9, 2018: Journal of Translational Medicine
https://www.readbyqxmd.com/read/29515971/the-expression-and-prognostic-impact-of-immune-cytolytic-activity-related-markers-in-human-malignancies-a-comprehensive-meta-analysis
#17
Constantinos Roufas, Dimitrios Chasiotis, Anestis Makris, Christodoulos Efstathiades, Christos Dimopoulos, Apostolos Zaravinos
Background: Recently, immune-checkpoint blockade has shown striking clinical results in different cancer patients. However, a significant inter-individual and inter-tumor variability exists among different cancers. The expression of the toxins granzyme A (GZMA) and perforin 1 (PRF1), secreted by effector cytotoxic T cells and natural killer (NK) cells, were recently used as a denominator of the intratumoral immune cytolytic activity (CYT). These levels are significantly elevated upon CD8+ T-cell activation as well as during a productive clinical response against immune-checkpoint blockade therapies...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29510614/expression-of-immunoproteasome-subunit-lmp7-in-breast-cancer-and-its-association-with-immune-related-markers
#18
Miseon Lee, In Hye Song, Sun-Hee Heo, Young-Ae Kim, In Ah Park, Won Seon Bang, Hye Seon Park, Gyungyub Gong, Hee Jin Lee
Purpose: In the presence of interferon, proteasome subunits are replaced by their inducible counterparts to form an immunoproteasome (IP) plays a key role in generation of antigenic peptides presented by MHC class I molecules, leading to elicitation of a T cell‒mediated immune response. Although the roles of IP in other cancers, and inflammatory diseases have been extensively studied, its significance in breast cancer is unclear. Materials and Methods: We investigated the expression of LMP7, an IP subunit, and its relationship with immune system components in two breast cancer cohorts...
February 26, 2018: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/29471435/immune-infiltration-in-invasive-lobular-breast-cancer
#19
Christine Desmedt, Roberto Salgado, Marco Fornili, Giancarlo Pruneri, Gert Van den Eynden, Gabriele Zoppoli, Françoise Rothé, Laurence Buisseret, Soizic Garaud, Karen Willard-Gallo, David Brown, Yacine Bareche, Ghizlane Rouas, Christine Galant, François Bertucci, Sherene Loi, Giuseppe Viale, Angelo Di Leo, Andrew R Green, Ian O Ellis, Emad A Rakha, Denis Larsimont, Elia Biganzoli, Christos Sotiriou
Background: Invasive lobular breast cancer (ILC) is the second most common histological subtype of breast cancer after invasive ductal cancer (IDC). Here, we aimed at evaluating the prevalence, levels, and composition of tumor-infiltrating lymphocytes (TILs) and their association with clinico-pathological and outcome variables in ILC, and to compare them with IDC. Methods: We considered two patient series with TIL data: a multicentric retrospective series (n = 614) and the BIG 02-98 study (n = 149 ILC and 807 IDC)...
February 20, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29464065/the-presence-of-pd-1-positive-tumor-infiltrating-lymphocytes-in-triple-negative-breast-cancers-is-associated-with-a-favorable-outcome-of-disease
#20
Gero Brockhoff, Stephan Seitz, Florian Weber, Florian Zeman, Monika Klinkhammer-Schalke, Olaf Ortmann, Anja Kathrin Wege
Triple negative breast cancer patients have a poor course of disease not least because of limited treatment options however immunotherapy by targeting the PD-1/PD-L1 checkpoint system is a promising strategy to improve the outcome. Here we systematically investigated the expression of PD-1 on tumor infiltrating lymphocytes and PD-L1 on both tumor and infiltrated immune cells. Moreover, the PD-L1 gene status in tumor cells was assessed. 103 tissue microarray samples derived from triple negative breast cancer specimens were immunohistochemically stained against PD-1 and PD-L1...
January 19, 2018: Oncotarget
keyword
keyword
56488
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"